Literature DB >> 18623083

The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells.

Nina Wagener1, Daniela Holland, Julia Bulkescher, Irena Crnković-Mertens, Karin Hoppe-Seyler, Hanswalter Zentgraf, Maria Pritsch, Stephan Buse, Jesco Pfitzenmaier, Axel Haferkamp, Markus Hohenfellner, Felix Hoppe-Seyler.   

Abstract

The enhancer of zeste homolog 2 (EZH2) gene has been recently linked to human malignancies where it may serve as a new target for cancer therapy. Here, we analyzed EZH2 expression in primary renal cell carcinoma (RCC) specimens and in nontumorous tissue samples from adult kidney. EZH2 transcripts were detectable in all RCC specimens examined. Expression levels were significantly higher in tumor tissue (p < or = 0.0001) than in samples from normal adult kidney. Moreover, inhibition of endogenous EZH2 expression in RCC cell lines by RNA interference (RNAi) led to reduced proliferation and increased apoptosis in RCC cells. These data show that EZH2 is overexpressed in RCC. Furthermore, they indicate that the EZH2 gene plays a role for both the proliferation and the apoptosis resistance of RCC cells. Targeted inhibition of EZH2 could therefore represent a novel strategy to improve the therapeutic response of RCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18623083     DOI: 10.1002/ijc.23683

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  34 in total

1.  Inhibition of EZH2 expression is associated with the proliferation, apoptosis and migration of SW620 colorectal cancer cells in vitro.

Authors:  He Song-Bing; Zhou Hao; Zhou Jian; Zhou Guo-Qiang; Han Tuo; Wan Dai-Wei; Gu Wen; Gao Lin; Zhang Yi; Xue Xiao-Feng; Zhang Li-Feng; Fei Min; Hi Shui-Qing; Yang Xiao-Dong; Zhu Xin-Guo; Wang Liang; Li De-Chun
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-27

2.  Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.

Authors:  Yong Wang; Yajing Chen; Hua Geng; Can Qi; Yunde Liu; Dan Yue
Journal:  Tumour Biol       Date:  2015-04-17

3.  HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase.

Authors:  Abhishek A Chakraborty; Eijiro Nakamura; Jun Qi; Amanda Creech; Jacob D Jaffe; Joshiawa Paulk; Jesse S Novak; Kshithija Nagulapalli; Samuel K McBrayer; Glenn S Cowley; Javier Pineda; Jiaxi Song; Yaoyu E Wang; Steven A Carr; David E Root; Sabina Signoretti; James E Bradner; William G Kaelin
Journal:  Sci Transl Med       Date:  2017-07-12       Impact factor: 17.956

4.  Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma.

Authors:  Michele Avissar-Whiting; Devin C Koestler; E Andres Houseman; Brock C Christensen; Karl T Kelsey; Carmen J Marsit
Journal:  Epigenetics       Date:  2011-06-01       Impact factor: 4.528

Review 5.  Priming the renal progenitor cell.

Authors:  Diana M Iglesias; Murielle M Akpa; Paul Goodyer
Journal:  Pediatr Nephrol       Date:  2014-01-12       Impact factor: 3.714

Review 6.  Epigenetic regulation in RCC: opportunities for therapeutic intervention?

Authors:  James Larkin; Xin Yi Goh; Marcus Vetter; Lisa Pickering; Charles Swanton
Journal:  Nat Rev Urol       Date:  2012-01-17       Impact factor: 14.432

7.  Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma.

Authors:  Akimasa Hayashi; Teppei Morikawa; Taketo Kawai; Haruki Kume; Shumpei Ishikawa; Yukio Homma; Masashi Fukayama
Journal:  Virchows Arch       Date:  2014-01-21       Impact factor: 4.064

8.  A novel EZH2 inhibitor induces synthetic lethality and apoptosis in PBRM1-deficient cancer cells.

Authors:  Kejia Huang; Rong Sun; Jiarong Chen; Qianye Yang; Yucheng Wang; Yang Zhang; Kun Xie; Tiantian Zhang; Rui Li; Qi Zhao; Liang Zou; Jian Li
Journal:  Cell Cycle       Date:  2020-02-24       Impact factor: 4.534

9.  Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.

Authors:  Nina Wagener; Stephan Macher-Goeppinger; Maria Pritsch; Johannes Hüsing; Karin Hoppe-Seyler; Peter Schirmacher; Jesco Pfitzenmaier; Axel Haferkamp; Felix Hoppe-Seyler; Markus Hohenfellner
Journal:  BMC Cancer       Date:  2010-10-04       Impact factor: 4.430

Review 10.  Drugging Chromatin in Cancer: Recent Advances and Novel Approaches.

Authors:  Sheng F Cai; Chun-Wei Chen; Scott A Armstrong
Journal:  Mol Cell       Date:  2015-11-19       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.